@article{oai:kanazawa-u.repo.nii.ac.jp:00014227,
 author = {Takami, Akiyoshi and Hayashi, Akiyoshi and Kita, Daisuke and Nishimura, Ryosei and Asakura, Hidesaku and Nakao, Shinji},
 issue = {1},
 journal = {Cancer Science},
 month = {Jan},
 note = {We describe an immunocompetent 19-year-old man with CD20-positive primary central nervous system (CNS) lymphoma refractory to chemotherapy and irradiation. After intraventricular administration of rituximab, a chimeric anti-CD20 monoclonal antibody, supplemented with autologous serum, a remarkable response developed to the CNS parenchymal lymphoma. Cytotoxicity assays showed that untreated patient's serum with rituximab, but not that of heat-inactivated patient's serum with rituximab or rituximab alone, induced potent rituximab-mediated cytotoxicity against tumor cells in the patient's cerebrospinal fluid, suggesting induction of complement-dependent cytotoxicity against CNS lymphoma. © 2006 Japanese Cancer Association., 医薬保健研究域医学系},
 pages = {80--83},
 title = {Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab},
 volume = {97},
 year = {2006}
}